Skip to main content
. 2020 Aug 4;7(18):2000906. doi: 10.1002/advs.202000906

Figure 5.

Figure 5

PA/PI‐ND enhanced the chemoimmunotherapeutic antitumor efficacy in CT26 tumor‐bearing BALB/c mice. a) Schedule of intravenous injection with different formulations in vivo (n = 6, black arrows represented administration time). b) Changes in tumor volume and c) body weight after intravenous injection with different formulations in vivo (**p < 0.01, ***p < 0.001, compared with PA/PI‐ND; #p < 0.05, ###p < 0.001, compared with PA‐ND, n = 6). d) Tumor weight at the endpoint (*p < 0.05, **p < 0.01, ***p < 0.001, compared with PA/PI‐ND; #p < 0.05, ###p < 0.001, compared with PA‐ND, n = 6). e) Microscopy images of ex vivo tumors after treatment with different samples. f) Immunohistochemical images of tumor tissue sections (H&E 400×, Ki67 200 ×, and TUNEL 20 × ).